NASDAQ:ANAB
AnaptysBio Inc Stock News
$23.94
+0.290 (+1.23%)
At Close: May 31, 2024
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
02:33pm, Thursday, 01'st Sep 2022 Benzinga
Upgrades
For iQIYI Inc (NASDAQ:IQ), UBS upgraded the previous rating of Neutral to Buy. For the second quarter, iQIYI had an EPS of $0.01, compared to year-ago quarter EPS of $0.27. At the moment, the
AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa
08:15pm, Wednesday, 31'st Aug 2022 GlobeNewswire Inc.
SAN DIEGO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced top-lin
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Lags Revenue Estimates
09:35pm, Monday, 08'th Aug 2022 Zacks Investment Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -21.05% and 80.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Lags Revenue Estimates
06:48pm, Monday, 08'th Aug 2022
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -21.05% and 80.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference
08:00pm, Friday, 05'th Aug 2022 GlobeNewswire Inc.
SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Da
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference
04:00pm, Friday, 05'th Aug 2022
SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan
Halozyme Therapeutics (HALO) Moves 7.3% Higher: Will This Strength Last?
11:22am, Friday, 08'th Jul 2022 Zacks Investment Research
Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
08:05pm, Thursday, 02'nd Jun 2022 GlobeNewswire Inc.
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanism
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Lags Revenue Estimates
10:55pm, Wednesday, 04'th May 2022 Zacks Investment Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -50.57% and 87.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update
08:15pm, Wednesday, 04'th May 2022 GlobeNewswire Inc.
SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
12:52pm, Thursday, 28'th Apr 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Moderna Seeks FDA Emergency Use Nod For COVID-19 Shot In Kids 2-6
Moderna Inc (NASDAQ: MRNA) submitt
AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates
08:15pm, Wednesday, 27'th Apr 2022 GlobeNewswire Inc.
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune
AnaptysBio, Inc. (ANAB) Soars 6.2%: Is Further Upside Left in the Stock?
11:05am, Tuesday, 26'th Apr 2022 Zacks Investment Research
AnaptysBio, Inc. (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term
AnaptysBio, Inc. (ANAB) Soars 6.2%: Is Further Upside Left in the Stock?
08:17am, Tuesday, 26'th Apr 2022
AnaptysBio, Inc. (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term
Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2022
02:03pm, Tuesday, 22'nd Mar 2022 Benzinga
Upgrades
For Procter & Gamble Co (NYSE:PG), Truist Securities upgraded the previous rating of Hold to Buy. For the second quarter, Procter & Gamble had an EPS of $1.66, compared to year-ago quarter EP
